Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06458712
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-14
First Post:
2024-06-07
Brief Title:
Study to Assess Safety Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Sponsor:
Duke Street Bio Ltd
Organization:
Duke Street Bio Ltd
Study Overview
Official Title:
Phase IaIb Open Label Multi-Centre Dose Escalation Study With Expansion Cohorts to Assess the Safety Tolerability and Activity of DSB2455 as Monotherapy or in Combination With Anti-Cancer Agents in Participants With Advanced Malignancies
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Open label multi-centre Phase Iab adaptive design study with an initial 2-stage inter-participant Dose Escalation Phase followed by a Dose Expansion Phase
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None